Slowing chronic kidney disease progression: results of prospective clinical trials in adults

Abstract

Chronic kidney disease is generally thought to be a progressive disorder regardless of etiology. Over the past 15 years, investigations into the mechanisms of disease progression and treatment designed to slow or halt disease progression have been conducted, largely in the adult kidney disease population. Intervention trials have demonstrated that lowering blood pressure in hypertensive patients and administration of drugs that block the renin–angiotensin aldosterone system are effective at slowing kidney disease progression, including diabetes, hypertension, and various glomerular diseases. In addition, novel strategies including anemia therapy with erythropoietin-stimulating agents have been conducted to determine whether treatment of this common complication of kidney disease can stabilize kidney function. Whereas substantial success has been achieved in more common forms of adult kidney disease such as diabetes and hypertension, slowing progression of some immune-mediated glomerular disease such as lupus nephritis and immunoglobulin A (IgA) nephropathy remain a great challenge. Moreover, there is no proven strategy, including multifactorial interventions, that clearly halts progressive chronic kidney disease that has been studied prospectively in a large-scale, long-term trial. The purpose of this review is to discuss these trials, as they form the underpinnings for current clinical practice guidelines in adults with chronic kidney disease.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    CAS  Google Scholar 

  2. 2.

    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G (2003) National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Ann Intern Med 139:137–147

    PubMed  Google Scholar 

  4. 4.

    National Kidney Foundation Kidney Disease Outcomes Quality Initiative (2002) K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis 39(1):108–115

    Google Scholar 

  5. 5.

    Hsu CY, Vittinghoff E, Lin F, Shlipak MG (2004) The incidence of end stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 141:95–101

    PubMed  Google Scholar 

  6. 6.

    US Renal Data System 2004 Annual Data Report. https://doi.org/wwwusrds.org. Accessed 09/25/2007

  7. 7.

    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456–1462

    CAS  PubMed  Google Scholar 

  8. 8.

    Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch SW, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators (2001) Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869

    CAS  Google Scholar 

  9. 9.

    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860

    CAS  Google Scholar 

  10. 10.

    Parving HH, Lehnert H, Brochner-Mortensen J, Gonis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group (2001) The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878

    CAS  Google Scholar 

  11. 11.

    Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G, Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941–1951

    CAS  PubMed  Google Scholar 

  12. 12.

    Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952–1961

    CAS  PubMed  Google Scholar 

  13. 13.

    Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zuccheli P, The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939–945

    CAS  PubMed  Google Scholar 

  14. 14.

    The GISEN (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Group (1997) Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857–1863

    Google Scholar 

  15. 15.

    Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 352:1252–1256

    CAS  PubMed  Google Scholar 

  16. 16.

    Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G (1999) Renoprotective properties of ACE inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359–364

    CAS  Google Scholar 

  17. 17.

    Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Bsile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G, REIN-2 Study Group (2005) Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 365:939–946

    PubMed  Google Scholar 

  18. 18.

    Wright JT, Bakris G, Greene T, Adodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Classock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG, African American Study of Kidney Disease and Hypertension Study Group (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 288:2421–2431

    CAS  PubMed  Google Scholar 

  19. 19.

    Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361:117–124

    CAS  PubMed  Google Scholar 

  20. 20.

    The Diabetes Control and Complications Research Group (1995) Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47:1703–1720

    Google Scholar 

  21. 21.

    UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853

    Google Scholar 

  22. 22.

    Fried LF, Orchard TJ, Kasiske BL (2001) Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59:260–269

    CAS  PubMed  Google Scholar 

  23. 23.

    Bianchi S, Bigazzi R, Caiazza A, Campese VM (2003) A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41:565–570

    CAS  PubMed  Google Scholar 

  24. 24.

    Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:23–33

    Google Scholar 

  25. 25.

    Tonelli M, Moyé L, Sacks FM, Kiberd B, Curhan G; Cholesterol and Recurrent Events (CARE) Trial Investigators (2003) Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138:98–104

    CAS  PubMed  Google Scholar 

  26. 26.

    Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA (2005) Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 149:408–413

    CAS  PubMed  Google Scholar 

  27. 27.

    Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G (1994) The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 330:877–884

    CAS  Google Scholar 

  28. 28.

    Levey AS, Adler S, Caggiula AW, England BK, Greene T, Hunsicker LG, Kusek JW, Rogers NL, Teschan PE (1996) Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease study. Am J Kidney Dis 5:652–663

    Google Scholar 

  29. 29.

    Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR (1991) Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 324:1743–1744

    Google Scholar 

  30. 30.

    Ma JZ, Ebben J, Xia H, Collins AJ (1999) Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610–619

    CAS  PubMed  Google Scholar 

  31. 31.

    Li S, Foley RN, Collins AJ (2004) Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 65:1864–1869

    PubMed  Google Scholar 

  32. 32.

    Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O (1997) Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176–185

    CAS  PubMed  Google Scholar 

  33. 33.

    Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC (2004) Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int 66:753–760

    PubMed  Google Scholar 

  34. 34.

    Singh AK, Szczech L, Tang KI, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098

    CAS  Google Scholar 

  35. 35.

    Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE (1994) A controlled trial of fish oil in IgA nephropathy. N Engl J Med 331:1194–1199

    Google Scholar 

  37. 37.

    Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rhem 34:945–950

    CAS  Google Scholar 

  38. 38.

    Austin HA, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL (1986) Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619

    Google Scholar 

  39. 39.

    Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745

    CAS  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971–980

    CAS  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343:1156–1162

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228

    CAS  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM (1992) A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 326:1373–1379

    CAS  PubMed  Google Scholar 

  44. 44.

    Cattran DC (2005) Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 16:1188–1194

    PubMed  Google Scholar 

  45. 45.

    Coggins CH, Collaborative Study of the Adult Idiopathic Nephrotic Syndrome Group (1979) A controlled study of short-term prednisone treatment in adults with membranous nephropathy. N Engl J Med 301:1301–1306

    Google Scholar 

  46. 46.

    Cattran DC, Delmore T, Roscoe J, Cole E, Cardella C, Charron R, Ritchie S (1989) A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 320:210–215

    CAS  Google Scholar 

  47. 47.

    Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P, Grassi C, Limido D, Pasquali S, Volpini T (1984) Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 310:945–950

    Google Scholar 

  48. 48.

    Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B (1989) A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320:8–13

    CAS  PubMed  Google Scholar 

  49. 49.

    Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL, North America Nephrotic Syndrome Study Group (2001) Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 59:1484–1490

    CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Robert D. Toto.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nguyen, T., Toto, R.D. Slowing chronic kidney disease progression: results of prospective clinical trials in adults. Pediatr Nephrol 23, 1409–1422 (2008). https://doi.org/10.1007/s00467-007-0737-2

Download citation

Keywords

  • Clinical trial
  • Hypertension
  • Diabetes
  • Anemia
  • Angiotensin-converting enzyme inhibitor
  • Angiotensin-receptor antagonist
  • Glomerulonephritis